Amylyx Pharmaceuticals annual stock-based compensation
2021
2022
2023
2024
2025
Amylyx Pharmaceuticals Stock-Based Compensation Growth & History (AMLX)
Amylyx Pharmaceuticals's stock-based compensation was $27.6M for fiscal 2025.
View full Amylyx Pharmaceuticals company overviewAmylyx Pharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $27.6M | −$5.4M | −16.32% |
| 2024 | 2024-12-31 | $33.0M | −$4.1M | −11.09% |
| 2023 | 2023-12-31 | $37.2M | $15.4M | +71.14% |
| 2022 | 2022-12-31 | $21.7M | $18.6M | +592.41% |
| 2021 | 2021-12-31 | $3.1M | — | — |
Amylyx Pharmaceuticals quarterly stock-based compensation
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $8.3M | $968,000 | +13.17% |
| Q1 2026 | 2026-03-31 | $6.1M | −$713,000 | −10.43% |
| Q4 2025 | 2025-12-31 | $6.4M | — | — |
| Q3 2025 | 2025-09-30 | $7.1M | $273,000 | +4.01% |
| Q2 2025 | 2025-06-30 | $7.3M | −$2.2M | −23.20% |
| Q1 2025 | 2025-03-31 | $6.8M | −$3.1M | −31.15% |
| Q3 2024 | 2024-09-30 | $6.8M | −$3.4M | −33.15% |
| Q2 2024 · Jun 30 | 2024-06-30 | $9.6M | −$380,000 | −3.82% |
| Q1 2024 | 2024-03-31 | $9.9M | $2.4M | +32.30% |
| Q4 2023 | 2023-12-31 | $9.5M | $3.4M | +56.53% |
| Q3 2023 | 2023-09-30 | $10.2M | $4.7M | +84.21% |
| Q2 2023 | 2023-06-30 | $9.9M | $4.2M | +74.35% |
| Q1 2023 | 2023-03-31 | $7.5M | $3.1M | +70.79% |
| Q4 2022 | 2022-12-31 | $6.1M | $5.0M | +458.30% |
| Q3 2022 | 2022-09-30 | $5.5M | $4.7M | +588.78% |
| Q2 2022 | 2022-06-30 | $5.7M | $5.0M | +768.65% |
| Q1 2022 | 2022-03-31 | $4.4M | $3.8M | +649.49% |
| Q4 2021 | 2021-12-31 | $1.1M | — | — |
| Q3 2021 | 2021-09-30 | $802,000 | — | — |
| Q2 2021 | 2021-06-30 | $657,000 | — | — |
| Q1 2021 | 2021-03-31 | $586,000 | — | — |
Amylyx Pharmaceuticals stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, Amylyx Pharmaceuticals's stock-based compensation increased from $3.1M to $27.6M, a change of $24.5M. The latest reported quarter, Q2 2026, shows $8.3M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Amylyx Pharmaceuticals source filings ↗